skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Balloon Coating with Rapamycin Using an On-site Coating Device

Journal Article · · Cardiovascular and Interventional Radiology
 [1];  [2]; ;  [1];  [3];  [4];  [1];  [3]
  1. Department of Diagnostic and Interventional Radiology, University Hospital of Tuebingen (Germany)
  2. Institute of Anatomy, University of Tuebingen (Germany)
  3. Translumina GmbH (Germany)
  4. Clinic of Thoracic and Cardiovascular Surgery, University Hospital of Tuebingen (Germany)

Purpose. The efficacy of drug-eluting balloons has been demonstrated in clinical trials. The drug predominantly used is paclitaxel because of its lipophilic properties and the rapid onset of action. The aim of the investigation was to evaluate the feasibility and efficacy of an alternative balloon coating with rapamycin that can be applied on site.MethodsThe balloon coating (3.0/18 and 3.0/12 mm, Cathy No. 4, Translumina GmbH) with rapamycin was conducted with a coating machine (Translumina GmbH). Concentrations were 2, 2 Multiplication-Sign 2, 3, and 4 %. Measurements regarding the amount of substance released to the vessel wall were carried out on explanted porcine coronaries by means of ultraviolet and visible-light spectroscopy. Inflation time varied between 30 and 120 s. The biological effect of the coating was evaluated in a porcine peripheral overstretch and stent implantation model. Results. The amount of rapamycin on the balloon surface ranged from 558 {+-} 108 {mu}g for the 2 % solution to 1,441 {+-} 228 {mu}g in the 4 % solution. An amount of 95 {+-} 63-193 {+-} 113 {mu}g was released into the vessel wall. The quantitative measurements of the angiographic examinations 4 weeks after treatment revealed a reduction of diameter stenosis from 20.6 {+-} 17.4 % in the control group to 11.6 {+-} 5.5 % in the drug-eluting balloon group. Conclusion. A balloon coating with rapamycin omitting an excipient is possible with a dose-adjustable coating machine. However, the biological effects are moderate, which make further optimization of the coating process and evaluation of appropriate excipients necessary.

OSTI ID:
22116050
Journal Information:
Cardiovascular and Interventional Radiology, Vol. 36, Issue 3; Other Information: Copyright (c) 2013 Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE); Country of input: International Atomic Energy Agency (IAEA); ISSN 0174-1551
Country of Publication:
United States
Language:
English